fbpx
Listen

National Veterinary Vaccines Company

| Learn about investment opportunities

National Veterinary Vaccines Company

Icon

The company, established in late 2019, aims to contribute to the demand in Arab countries for essential, commonly used vaccines, such as those for livestock foot-and mouth disease, bird flu and Newcastle disease, among others.

Icon

Free Zone Port of Sohar-Sultanate of Oman

Contact address
  • Icon Ghala, Bousher, Muscat Governorate
    (+968) 993 12289
  • Icon ali.alsahmy@nvvco.com
  • Icon P.O. Box61, Zip code: 134
Icon
Designed capacity

The project will be implemented in two phases:

  • – Phase I: targeting the aseptic filling and production of 114.5 million doses of different vaccines over an expansion plan period of five years.
  • – Phase II: production of 144 million doses of different vaccines from year 5 onward.

Icon
Capital and shareholders

The Initial capital is OMR 200 thousand, and shareholders are:

  • – AAAID: 50%
  • – Oman Food Investment Holding Company (SAOC): 50%
  • AAAID

  • Oman Food Investment Holding Company (SAOC)

Icon
Average sales

The company's estimated sales at stability year (the tenth year of production) are estimated at USD 52.7 million.

Icon
Market share

The market share is estimated at 12%.

Icon
Company products

- Foot Mouth Disease (FMD) vaccine
- Newcastle vaccine, bird flu vaccine, and others.

Icon
Investment cost

The total investment cost is estimated at USD 55 million, representing an investment cost of USD 30 million at phase I and USD 25 million at phase II.

Icon
Financial indicators

  • IRR: 35%
  • NPV (10% discount rate): OMR 48.1 million

Icon
Required finance

- The two phases are financed by 60% loan 40% equity

Learn about the investment opportunities in:National Veterinary Vaccines Company

01

Participation in equity and/or Provision of loans to complete implementation of project components.